Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Oral Dexmedetomidine Versus Midazolam as Anesthetic Premedication in Children Undergoing Congenital Heart Surgery.

Anesthesiology and pain medicine

Faritus SZ, Khazaee-Koohpar M, Ziyaeifard M, Mehrabanian MJ.
PMID: 26161325
Anesth Pain Med. 2015 Jun 22;5(3):e25032. doi: 10.5812/aapm.5(3)2015.25032. eCollection 2015 Jun.

BACKGROUND: Premedication is required for reducing anxiety and child's struggling against mask acceptance on anesthesia in pediatric surgery for congenital heart disease. Midazolam has been widely used for this purpose, but because of its side effects, finding an effective...

Cite
Faritus SZ, Khazaee-Koohpar M, Ziyaeifard M, et al. Oral Dexmedetomidine Versus Midazolam as Anesthetic Premedication in Children Undergoing Congenital Heart Surgery. Anesth Pain Med. 2015;5(3):e25032doi: 10.5812/aapm.5(3)2015.25032.
Faritus, S. Z., Khazaee-Koohpar, M., Ziyaeifard, M., & Mehrabanian, M. J. (2015). Oral Dexmedetomidine Versus Midazolam as Anesthetic Premedication in Children Undergoing Congenital Heart Surgery. Anesthesiology and pain medicine, 5(3), e25032. https://doi.org/10.5812/aapm.5(3)2015.25032
Faritus, Seyedeh Zahra, et al. "Oral Dexmedetomidine Versus Midazolam as Anesthetic Premedication in Children Undergoing Congenital Heart Surgery." Anesthesiology and pain medicine vol. 5,3 (2015): e25032. doi: https://doi.org/10.5812/aapm.5(3)2015.25032
Faritus SZ, Khazaee-Koohpar M, Ziyaeifard M, Mehrabanian MJ. Oral Dexmedetomidine Versus Midazolam as Anesthetic Premedication in Children Undergoing Congenital Heart Surgery. Anesth Pain Med. 2015 Jun 22;5(3):e25032. doi: 10.5812/aapm.5(3)2015.25032. eCollection 2015 Jun. PMID: 26161325; PMCID: PMC4493729.
Copy Download .nbib Format: NLM
The Efficacy and Safety of Clonazepam in Patients with Anxiety Disorder Taking Newer Antidepressants: A Multicenter Naturalistic Study.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Wang SM, Kim JB, Sakong JK, Suh HS, Oh KS, Woo JM, Yoo SW, Lee SM, Lee SY, Lim SW, Cho SJ, Chee IS, Chae JH, Hong JP, Lee KU.
PMID: 27121429
Clin Psychopharmacol Neurosci. 2016 May 31;14(2):177-83. doi: 10.9758/cpn.2016.14.2.177.

OBJECTIVE: This study compared the efficacy and tolerability of clonazepam with other benzodiazepines in patients with anxiety disorders.METHODS: Inclusion criteria were as follows: age >20 years, diagnosis of anxiety disorder according to the Diagnostic and Statistical Manual of Mental...

Cite
Wang SM, Kim JB, Sakong JK, et al. The Efficacy and Safety of Clonazepam in Patients with Anxiety Disorder Taking Newer Antidepressants: A Multicenter Naturalistic Study. Clin Psychopharmacol Neurosci. 2016;14(2):177-83doi: 10.9758/cpn.2016.14.2.177.
Wang, S. M., Kim, J. B., Sakong, J. K., Suh, H. S., Oh, K. S., Woo, J. M., Yoo, S. W., Lee, S. M., Lee, S. Y., Lim, S. W., Cho, S. J., Chee, I. S., Chae, J. H., Hong, J. P., & Lee, K. U. (2016). The Efficacy and Safety of Clonazepam in Patients with Anxiety Disorder Taking Newer Antidepressants: A Multicenter Naturalistic Study. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 14(2), 177-83. https://doi.org/10.9758/cpn.2016.14.2.177
Wang, Sheng-Min, et al. "The Efficacy and Safety of Clonazepam in Patients with Anxiety Disorder Taking Newer Antidepressants: A Multicenter Naturalistic Study." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 14,2 (2016): 177-83. doi: https://doi.org/10.9758/cpn.2016.14.2.177
Wang SM, Kim JB, Sakong JK, Suh HS, Oh KS, Woo JM, Yoo SW, Lee SM, Lee SY, Lim SW, Cho SJ, Chee IS, Chae JH, Hong JP, Lee KU. The Efficacy and Safety of Clonazepam in Patients with Anxiety Disorder Taking Newer Antidepressants: A Multicenter Naturalistic Study. Clin Psychopharmacol Neurosci. 2016 May 31;14(2):177-83. doi: 10.9758/cpn.2016.14.2.177. PMID: 27121429; PMCID: PMC4857865.
Copy Download .nbib Format: NLM
Measures to improve the comfort of cataract surgery patients: a systematic review and meta-analysis.

Annals of palliative medicine

Zeng K, Li Q, Xi W, Qiao Y.
PMID: 34872309
Ann Palliat Med. 2021 Nov;10(11):11849-11858. doi: 10.21037/apm-21-2945.

BACKGROUND: Improving patient comfort can provide patients with a better experience during surgery and reflect the high-quality of hospital medical services. This study conducted a systematic review and meta-analysis of several recent academic reports on improving patient comfort in...

Cite
Zeng K, Li Q, Xi W, et al. Measures to improve the comfort of cataract surgery patients: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(11):11849-11858doi: 10.21037/apm-21-2945.
Zeng, K., Li, Q., Xi, W., & Qiao, Y. (2021). Measures to improve the comfort of cataract surgery patients: a systematic review and meta-analysis. Annals of palliative medicine, 10(11), 11849-11858. https://doi.org/10.21037/apm-21-2945
Zeng, Kun, et al. "Measures to improve the comfort of cataract surgery patients: a systematic review and meta-analysis." Annals of palliative medicine vol. 10,11 (2021): 11849-11858. doi: https://doi.org/10.21037/apm-21-2945
Zeng K, Li Q, Xi W, Qiao Y. Measures to improve the comfort of cataract surgery patients: a systematic review and meta-analysis. Ann Palliat Med. 2021 Nov;10(11):11849-11858. doi: 10.21037/apm-21-2945. PMID: 34872309.
Copy Download .nbib Format: NLM
Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand.

BJGP open

Gulbransen G, Xu W, Arroll B.
PMID: 32019776
BJGP Open. 2020 May 01;4(1). doi: 10.3399/bjgpopen20X101010. Print 2020.

BACKGROUND: Cannabidiol (CBD) is the non-euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977) were amended, allowing doctors to prescribe CBD. Therapeutic benefit and tolerability of CBD remains unclear.AIM: To review the changes in...

Cite
Gulbransen G, Xu W, Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020;4(1)doi: 10.3399/bjgpopen20X101010.
Gulbransen, G., Xu, W., & Arroll, B. (2020). Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP open, 4(1), . https://doi.org/10.3399/bjgpopen20X101010
Gulbransen, Graham, et al. "Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand." BJGP open vol. 4,1 (2020). doi: https://doi.org/10.3399/bjgpopen20X101010
Gulbransen G, Xu W, Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020 May 01;4(1). doi: 10.3399/bjgpopen20X101010. Print 2020. PMID: 32019776; PMCID: PMC7330185.
Copy Download .nbib Format: NLM
Efficacy and Safety of Clidinium/Chlordiazepoxide as an Add-on Therapy in Functional Dyspepsia: A Randomized, Controlled, Trial.

Journal of neurogastroenterology and motility

Puasripun S, Thinrungroj N, Pinyopornpanish K, Kijdamrongthum P, Leerapun A, Chitapanarux T, Thongsawat S, Praisontarangkul OA.
PMID: 32235033
J Neurogastroenterol Motil. 2020 Apr 30;26(2):259-266. doi: 10.5056/jnm19186.

BACKGROUND/AIMS: The treatment of refractory functional dyspepsia (FD) is a challenge. Clidinium/chlordiazepoxide is a combination of antispasmodic and anxiolytic drugs that has been used as an adjunct treatment for FD in clinical practice with limited supporting evidence of efficacy....

Cite
Puasripun S, Thinrungroj N, Pinyopornpanish K, et al. Efficacy and Safety of Clidinium/Chlordiazepoxide as an Add-on Therapy in Functional Dyspepsia: A Randomized, Controlled, Trial. J Neurogastroenterol Motil. 2020;26(2):259-266doi: 10.5056/jnm19186.
Puasripun, S., Thinrungroj, N., Pinyopornpanish, K., Kijdamrongthum, P., Leerapun, A., Chitapanarux, T., Thongsawat, S., & Praisontarangkul, O. A. (2020). Efficacy and Safety of Clidinium/Chlordiazepoxide as an Add-on Therapy in Functional Dyspepsia: A Randomized, Controlled, Trial. Journal of neurogastroenterology and motility, 26(2), 259-266. https://doi.org/10.5056/jnm19186
Puasripun, Siripa, et al. "Efficacy and Safety of Clidinium/Chlordiazepoxide as an Add-on Therapy in Functional Dyspepsia: A Randomized, Controlled, Trial." Journal of neurogastroenterology and motility vol. 26,2 (2020): 259-266. doi: https://doi.org/10.5056/jnm19186
Puasripun S, Thinrungroj N, Pinyopornpanish K, Kijdamrongthum P, Leerapun A, Chitapanarux T, Thongsawat S, Praisontarangkul OA. Efficacy and Safety of Clidinium/Chlordiazepoxide as an Add-on Therapy in Functional Dyspepsia: A Randomized, Controlled, Trial. J Neurogastroenterol Motil. 2020 Apr 30;26(2):259-266. doi: 10.5056/jnm19186. PMID: 32235033; PMCID: PMC7176503.
Copy Download .nbib Format: NLM
Young offender drug use: knowledge and perceptions of Juvenile Justice Centre youth workers.

Drug and alcohol review

Howard J, Zibert E.
PMID: 16840117
Drug Alcohol Rev. 1994;13(1):47-55. doi: 10.1080/09595239400185721.

Juvenile Justice Centre youth workers in New South Wales (n = 106) were surveyed by questionnaire as to their knowledge and perceptions of alcohol and other drug issues of those in their care. Some background variables were also collected....

Cite
Howard J, Zibert E. Young offender drug use: knowledge and perceptions of Juvenile Justice Centre youth workers. Drug Alcohol Rev. 1994;13(1):47-55doi: 10.1080/09595239400185721.
Howard, J., & Zibert, E. (1994). Young offender drug use: knowledge and perceptions of Juvenile Justice Centre youth workers. Drug and alcohol review, 13(1), 47-55. https://doi.org/10.1080/09595239400185721
Howard, J, and Zibert, E. "Young offender drug use: knowledge and perceptions of Juvenile Justice Centre youth workers." Drug and alcohol review vol. 13,1 (1994): 47-55. doi: https://doi.org/10.1080/09595239400185721
Howard J, Zibert E. Young offender drug use: knowledge and perceptions of Juvenile Justice Centre youth workers. Drug Alcohol Rev. 1994;13(1):47-55. doi: 10.1080/09595239400185721. PMID: 16840117.
Copy Download .nbib Format: NLM
Impact of Lavender on Pain and Anxiety Levels Associated With Spine Procedures.

The Ochsner journal

Grabnar M, Roach MJ, Abd-Elsayed A, Kim C.
PMID: 34984050
Ochsner J. 2021;21(4):358-363. doi: 10.31486/toj.21.0013.

No abstract available.

Cite
Grabnar M, Roach MJ, Abd-Elsayed A, et al. Impact of Lavender on Pain and Anxiety Levels Associated With Spine Procedures. Ochsner J. 2021;21(4):358-363doi: 10.31486/toj.21.0013.
Grabnar, M., Roach, M. J., Abd-Elsayed, A., & Kim, C. (2021). Impact of Lavender on Pain and Anxiety Levels Associated With Spine Procedures. The Ochsner journal, 21(4), 358-363. https://doi.org/10.31486/toj.21.0013
Grabnar, Maria, et al. "Impact of Lavender on Pain and Anxiety Levels Associated With Spine Procedures." The Ochsner journal vol. 21,4 (2021): 358-363. doi: https://doi.org/10.31486/toj.21.0013
Grabnar M, Roach MJ, Abd-Elsayed A, Kim C. Impact of Lavender on Pain and Anxiety Levels Associated With Spine Procedures. Ochsner J. 2021;21(4):358-363. doi: 10.31486/toj.21.0013. PMID: 34984050; PMCID: PMC8675619.
Copy Download .nbib Format: NLM
Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents.

Behavioural processes

Misslin R, Belzung C, Vogel E.
PMID: 24897671
Behav Processes. 1989;18(1):119-32. doi: 10.1016/S0376-6357(89)80010-5. Epub 2014 Apr 15.

In order to teat the behavioural value of a two-chambered light/dark choice procedure used for pharmacological studies, we investigated the effects of several internal and external factors on two variables: the time spent by mice in the lit box...

Cite
Misslin R, Belzung C, Vogel E. Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents. Behav Processes. 2014;18(1):119-32doi: 10.1016/S0376-6357(89)80010-5.
Misslin, R., Belzung, C., & Vogel, E. (1989). Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents. Behavioural processes, 18(1), 119-32. https://doi.org/10.1016/S0376-6357(89)80010-5
Misslin, R, et al. "Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents." Behavioural processes vol. 18,1 (1989): 119-32. doi: https://doi.org/10.1016/S0376-6357(89)80010-5
Misslin R, Belzung C, Vogel E. Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents. Behav Processes. 1989;18(1):119-32. doi: 10.1016/S0376-6357(89)80010-5. Epub 2014 Apr 15. PMID: 24897671.
Copy Download .nbib Format: NLM
Flumazenil antagonizes the effect of diazepam on negative contrast in one-way avoidance learning.

Behavioural pharmacology

Torres MC, Morales A, Megías JL, Cándido A, Maldonado A.
PMID: 11224244
Behav Pharmacol. 1994 Oct;5(6):637-641. doi: 10.1097/00008877-199410000-00010.

The main aim of the present work was to study whether the effect of diazepam upon successive negative contrast in one-way avoidance learning-induced by shifting rats from a large reward (30s spent in the safe compartment) to a small...

Cite
Torres MC, Morales A, Megías JL, et al. Flumazenil antagonizes the effect of diazepam on negative contrast in one-way avoidance learning. Behav Pharmacol. 1994;5(6):637-641doi: 10.1097/00008877-199410000-00010.
Torres, M. C., Morales, A., Megías, J. L., Cándido, A., & Maldonado, A. (1994). Flumazenil antagonizes the effect of diazepam on negative contrast in one-way avoidance learning. Behavioural pharmacology, 5(6), 637-641. https://doi.org/10.1097/00008877-199410000-00010
Torres, M.C., et al. "Flumazenil antagonizes the effect of diazepam on negative contrast in one-way avoidance learning." Behavioural pharmacology vol. 5,6 (1994): 637-641. doi: https://doi.org/10.1097/00008877-199410000-00010
Torres MC, Morales A, Megías JL, Cándido A, Maldonado A. Flumazenil antagonizes the effect of diazepam on negative contrast in one-way avoidance learning. Behav Pharmacol. 1994 Oct;5(6):637-641. doi: 10.1097/00008877-199410000-00010. PMID: 11224244.
Copy Download .nbib Format: NLM
Pasteur Euroconference on future therapies for an anxious world.

Expert opinion on investigational drugs

Briley M, Fillion G.
PMID: 15991924
Expert Opin Investig Drugs. 1998 Jan;7(1):113-6. doi: 10.1517/13543784.7.1.113.

The aim of this meeting was to explore the molecular targets for tomorrow's drugs with a group of European and North American speakers from the pharmaceutical industry and academia presenting both data and ideas. Several speakers considered 5-hydroxytryptamine(1B/D) (5-HT(1B/D))...

Cite
Briley M, Fillion G. Pasteur Euroconference on future therapies for an anxious world. Expert Opin Investig Drugs. 1998;7(1):113-6doi: 10.1517/13543784.7.1.113.
Briley, M., & Fillion, G. (1998). Pasteur Euroconference on future therapies for an anxious world. Expert opinion on investigational drugs, 7(1), 113-6. https://doi.org/10.1517/13543784.7.1.113
Briley, M, and Fillion, G. "Pasteur Euroconference on future therapies for an anxious world." Expert opinion on investigational drugs vol. 7,1 (1998): 113-6. doi: https://doi.org/10.1517/13543784.7.1.113
Briley M, Fillion G. Pasteur Euroconference on future therapies for an anxious world. Expert Opin Investig Drugs. 1998 Jan;7(1):113-6. doi: 10.1517/13543784.7.1.113. PMID: 15991924.
Copy Download .nbib Format: NLM
Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Lee JO, Kim JW, Kang HJ, Hong JP, Kim JM.
PMID: 30466218
Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):461-468. doi: 10.9758/cpn.2018.16.4.461.

OBJECTIVE: Cognitive disturbance is one of the major symptoms of depression and may be improved by treatment with antidepressants. This study aimed to investigate the predictors of cognitive improvement in patients with major depressive disorder (MDD) who were taking...

Cite
Lee JO, Kim JW, Kang HJ, et al. Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder. Clin Psychopharmacol Neurosci. 2018;16(4):461-468doi: 10.9758/cpn.2018.16.4.461.
Lee, J. O., Kim, J. W., Kang, H. J., Hong, J. P., & Kim, J. M. (2018). Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 16(4), 461-468. https://doi.org/10.9758/cpn.2018.16.4.461
Lee, Jeong-Ok, et al. "Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 16,4 (2018): 461-468. doi: https://doi.org/10.9758/cpn.2018.16.4.461
Lee JO, Kim JW, Kang HJ, Hong JP, Kim JM. Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder. Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):461-468. doi: 10.9758/cpn.2018.16.4.461. PMID: 30466218; PMCID: PMC6245296.
Copy Download .nbib Format: NLM
Pharmacological Treatment of Anxiety Disorders: The Role of the HPA Axis.

Frontiers in psychiatry

Tafet GE, Nemeroff CB.
PMID: 32499732
Front Psychiatry. 2020 May 15;11:443. doi: 10.3389/fpsyt.2020.00443. eCollection 2020.

Stress in general, and early life stress in particular, has been associated with the development of anxiety and mood disorders. The molecular, biological and psychological links between stress exposure and the pathogenesis of anxiety and mood disorders have been...

Cite
Tafet GE, Nemeroff CB. Pharmacological Treatment of Anxiety Disorders: The Role of the HPA Axis. Front Psychiatry. 2020;11:443doi: 10.3389/fpsyt.2020.00443.
Tafet, G. E., & Nemeroff, C. B. (2020). Pharmacological Treatment of Anxiety Disorders: The Role of the HPA Axis. Frontiers in psychiatry, 11443. https://doi.org/10.3389/fpsyt.2020.00443
Tafet, Gustavo E, and Nemeroff, Charles B. "Pharmacological Treatment of Anxiety Disorders: The Role of the HPA Axis." Frontiers in psychiatry vol. 11 (2020): 443. doi: https://doi.org/10.3389/fpsyt.2020.00443
Tafet GE, Nemeroff CB. Pharmacological Treatment of Anxiety Disorders: The Role of the HPA Axis. Front Psychiatry. 2020 May 15;11:443. doi: 10.3389/fpsyt.2020.00443. eCollection 2020. PMID: 32499732; PMCID: PMC7243209.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries